Stocks in the News: Analyst Coverage on Encana, Unisys, Salix, Cerus and Eli Lilly

NEW YORK, December 17, 2014 /PRNewswire/ --

Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Encana (NYSE: ECA), Unisys (NYSE: UIS), Salix (NASDAQ: SLXP), Cerus (NASDAQ: CERS), and Eli Lilly (NYSE: LLY). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links at the bottom.

--

Analyst Update: Spending Plan Updates,Appointments,Inventory Targets, andFDA Approvals
Reviewed by: Rohit Tuli, CFA®

The US stock market on Tuesday witnessed its most volatile session since mid-October. Markets ended on a negative note amid slumping oil prices and growing chaos in Russia, represented by a massive decline of the ruble. The NASDAQ Composite edged 1.24% lower, the Dow Jones Industrial Average declined 0.65% and the S&P 500 fell 0.85%. A global emerging -market selloff which started on Monday, further pressurized Asia and the Asian stock market on Tuesday, which ended the day in red. On the other hand, the European Markets on December 16, 2014 closed on a positive note led by a surge in energy shares.  Further, positive data from a German analyst, an investor sentiment ZEW survey and a fund manager survey from Bank of America Merrill Lynch helped sustain the investor sentiment in the European Market.

Undeterred by the continued slump in crude oil prices, the Calgary, Alberta-based Encana Corporation (Encana) announced 2015 capital program of between $2.7 billion and $2.9 billion, which is above the Company's planned 2014 spending target. Encana said that 80% of its spending in 2015 will be focused on four of its highest margin growth plays; the Montney, Duvernay, Eagle Ford and Permian. Click on the report below to find out about shareholders' reaction to Encana's 2015 spending plan.

Unisys Corporation (Unisys) has named Peter A. Altabef as its new President and CEO. In addition, the Company announced that Paul E. Weaver, currently interim Chairman of the Unisys board, will become Chairman. The changes come into effect from January 1, 2015. Click on the report below to know more about Unisys' new chief.

Salix Pharmaceuticals, Ltd. (Salix) announced plans to bring down the wholesaler inventory levels to the Company's target of approximately three months by the end of 2015 - one year earlier than previously announced. Salix said that the move to accelerate reduction in inventory levels reflects views expressed by its largest shareholders. Click on the link below to know more about Salix's inventory reduction plans and updates on earnings outlook.

Cerus Corporation (Cerus) announced that the U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for plasma that reduces the risk of transfusion-transmitted infection (TTI) when treating patients requiring therapeutic plasma transfusion. Shares of Cerus rallied over 22% in after-hours trading session on Tuesday. Click on the link below to find out how Cerus' new system scores better over existing tests.

Eli Lilly and Co. (Eli Lilly) announced that the U.S. Food and Drug Administration (FDA) has approved use of the Company's CYRAMZA (ramucirumab) drug in combination with docetaxel, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. This marks the third FDA approval for CYRAMZA. Find out more about the Eli Lilly's CYRAMZA by clicking on the report below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

ECA Research Report: ( http://get.realtimeequities.com/pdf/?c=Encana&d=17-Dec-2014&s=ECA ),

UIS Research Report: ( http://get.realtimeequities.com/pdf/?c=Unisys&d=17-Dec-2014&s=UIS ),

SLXP Research Report: ( http://get.realtimeequities.com/pdf/?c=Salix&d=17-Dec-2014&s=SLXP ),

CERS Research Report: ( http://get.realtimeequities.com/pdf/?c=Cerus&d=17-Dec-2014&s=CERS ),

LLY Research Report: ( http://get.realtimeequities.com/pdf/?c=Eli%20Lilly&d=17-Dec-2014&s=LLY ). ============

--

About Realtime Equities  

Tired of missing trades? In a world where information travels at the speed of light, you can't afford to be out of touch. Get an actionable source of information. Find the best opportunities available in real-time. Don't waste time trying to chase the news, get ahead of it with Realtime Equities. We find information as it happens and send it out to our subscribers in our e-alerts. Our focus is to find companies positioned to see upward momentum, delivering alerts to your inbox as the event unfolds in realtime. Join us in our battle to beat the markets, you'll be happy you did.

We are proud to serve professional traders, financial advisors, hedge funds and experience individual investors including some of the top firms on wall-street today. For more information about our service offerings and subscriptions, please visit our website or reach out to our sales staff. Advanced subscription packages are available to qualifying institutional clients and accredited investors, please speak with your account manager to learn more about these custom opportunities.

If you enjoyed today's content, subscribe to our live updates here: ( http://get.realtimeequities.com/updates )

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Realtime Equities, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Realtime Equities in this article or report according to the procedures outlined by Realtime Equities. Realtime Equities is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.realtimeequities.com/editors

Contact Information: If you need to reach out to us about this release, please do so at:

Compliance Department

Toll Free: 1-800-632-0568

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE RealtimeEquities.com